IL-17A REVERTS THE REDUCTION IN CD8+ T CELL RESPONSE GENERATED BY ANTI-CD20 TREATMENT

FIOCCA VERNENGO FACUNDO; BECCARIA CRISTIAN GABRIEL; ALMADA LAURA; ARAUJO FURLÁN CINTIA; TOSELLO BOARI JIMENA; GOROSITO SERRÁN MELISA; GAZZONI YAMILA; MONTES CAROLINA LUCÍA; ACOSTA RODRÍGUEZ EVA V.; GRUPPI ADRIANA

Mar del Plata

Congreso; Reunión conjunta SAIC SAI SAFIS 2018; 2018

Anti-CD20 therapy, that depletes B cells, is widely used to treat autoimmunity and lymphomas. B cells can reg- ulate T cell responses because they have antibody in- dependent functions, such as antigen presentation and cytokine secretion. To evaluate the effect of anti-CD20 treatment on CD8+T cell response we used the experimental model of Trypanosoma cruzi infection, since CD8+T cells are essential for infection control.For that, anti-CD20 mAb was injected eight days before infection with 5000 trypomastigotes, to deplete B cells and CD8+ T cells response was analyzed at different days post infection (dpi). Infected control mice were injected with an isotype antibody. At 20 dpi, B-cell depleted mice (BcD) exhibited higher parasitism (determined by parasite DNA quantification by RT-PCR) in the spleen, liver and heart than controls (p